Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple statements are not supported by the provided FDA label excerpts, including several oncology claims presented as effectiveness and several mechanistic/limitation and research-combination claims. While some mechanism and immune-mediated adverse reaction claims are supported, overall alignment is poor due to several absent-from-label items and partially supported indications lacking labeled specifics.
Category Scores
Accurate Statements
Keytruda (pembrolizumab) is a programmed death receptor-1 (PD-1) inhibitor.
11 DESCRIPTION: Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody.
Keytruda blocks the PD-1 receptor on T-cells.
12.1 Mechanism of Action: Pembrolizumab binds to the PD-1 receptor and blocks interaction with PD-L1/PD-L2.
Keytruda can cause severe side effects including pneumonitis.
5.1 Severe and Fatal Immune-Mediated Adverse Reactions (Immune-Mediated Pneumonitis): Immune-mediated pneumonitis described as can be severe/fatal.
Keytruda can cause severe side effects including colitis.
5.1 Severe and Fatal Immune-Mediated Adverse Reactions (Immune-Mediated Colitis): Immune-mediated colitis described as can be severe/fatal.
Keytruda can cause severe side effects including hepatitis.
5.1 Severe and Fatal Immune-Mediated Adverse Reactions (Hepatotoxicity and Immune-Mediated Hepatitis): Immune-mediated hepatitis described as can be severe/fatal.
Keytruda is FDA-approved for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression after platinum-containing chemotherapy.
1.4 Head and Neck Squamous Cell Cancer: Indication includes recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
Unsupported Statements
Keytruda is FDA-approved for the treatment of unresectable or metastatic melanoma regardless of BRAF mutation status.
Provided label excerpt for melanoma states unresectable or metastatic melanoma but does not address BRAF mutation status (so the 'regardless of BRAF mutation status' qualifier is not supported by the excerpt).
Keytruda is FDA-approved for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression.
Provided label excerpt specifies PD-L1 criteria (e.g., TPS ≥1%) and other requirements; the claim is vague ('high PD-L1 expression') and does not specify labeled thresholds/settings.
Keytruda is FDA-approved for refractory classical Hodgkin lymphoma (cHL) or for cHL relapsed after autologous hematopoietic stem cell transplantation (ASCT).
Label excerpt supports relapsed or refractory cHL, but the excerpt provided does not confirm ASCT-specific wording.
Studies have shown Keytruda can be effective in treating triple-negative breast cancer (TNBC).
Label excerpt supports specific TNBC indications (high-risk early-stage with neoadjuvant chemotherapy regimen and PD-L1/CPS criteria for certain combination indications); the claim is general and does not specify labeled requirements.
Keytruda has shown promise in treating pancreatic cancer.
No pancreatic cancer indication/mechanism claim is present in the provided label excerpts.
Researchers are investigating the use of Keytruda in treating glioblastoma.
No glioblastoma research/investigation statement is present in the provided label excerpts.
Keytruda has been shown to be effective in treating multiple myeloma.
No multiple myeloma indication/effectiveness statement is present in the provided label excerpts.
Keytruda reduces the activity of immunosuppressive cells such as regulatory T-cells.
No regulatory T-cell activity statement is present in the provided label excerpts.
Cancer cells can develop resistance to Keytruda, reducing its effectiveness over time.
No resistance-over-time limitation statement is present in the provided label excerpts.
Researchers are investigating Keytruda in combination with other immunotherapies.
No investigation/combination research statement is present in the provided label excerpts.
Researchers are investigating Keytruda in combination with chemotherapy.
No investigation/combination research statement is present in the provided label excerpts.
Researchers are investigating Keytruda in combination with targeted therapies.
No investigation/combination research statement is present in the provided label excerpts.
Contradictions
Important Omissions
Dosage and administration details (e.g., dosing regimen, dose modifications) were not evaluated because no dosage/administration claims were provided, but this is material when assessing label alignment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several oncology effectiveness/indication and mechanistic/limitation statements are not supported by the provided label excerpts, which could lead to inaccurate labeling of uses or claims beyond what is supported. The immune-mediated adverse reaction claims evaluated (pneumonitis/colitis/hepatitis) are supported by the label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple claims are absent from the provided FDA label excerpts and several indication statements are overly general or include qualifiers not supported by the excerpt (e.g., BRAF status, 'high PD-L1', ASCT wording, TNBC generality, and effectiveness/resistance/research-combination claims).
Suggested Improvement
Restrict statements to the exact labeled indications and labeled biomarker criteria as written in the provided Indications section, remove or rephrase any non-label research/effectiveness claims (pancreatic cancer, glioblastoma, multiple myeloma, resistance, combination investigation), and ensure any mechanistic claims match the label wording (PD-1/PD-L1 pathway inhibition) without adding unsupported specific cell-type effects.